Search the Community
Showing results for tags 'scientific advisory board'.
Found 4 results
-
LUNGevity Foundation is proud to announce that Drew Moghanaki, MD, MPH, has joined its distinguished Scientific Advisory Board. Dr. Moghanaki is a highly regarded expert in the field of radiation oncology and leads the Clinical Research program at Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, Virginia. Dr. Moghanaki has been instrumental in bringing more than $34 million in funding to improve outcomes for lung cancer patients through a phase III lung cancer trial for veterans and a key VA partnership to increase access to lung cancer screening. LUNGevity’s Scientific Advisory Board oversees the Foundation’s scientific strategy and ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of all people diagnosed with lung cancer. LUNGevity’s awardees are working to improve our ability to detect, diagnose, and treat lung cancer, as well as prevent its recurrence. LUNGevity is the only lung cancer non-profit with a long-term, strategic focus on the early detection of lung cancer. “We are thrilled to have Dr. Moghanaki join LUNGevity’s Scientific Advisory Board,” said Andrea Ferris, president of LUNGevity Foundation. “He brings expertise in radiation oncology as well as a deep knowledge of the VA healthcare system. We are excited to have his unique perspective and expertise to help guide our research program.” Read the full press release here. -
LUNGevity Foundation is proud to announce that Drew Moghanaki, MD, MPH, has joined its distinguished Scientific Advisory Board. Dr. Moghanaki is a highly regarded expert in the field of radiation oncology and leads the Clinical Research program at Hunter Holmes McGuire Veterans Affairs Medical Center in Richmond, Virginia. Dr. Moghanaki has been instrumental in bringing more than $34 million in funding to improve outcomes for lung cancer patients through a phase III lung cancer trial for veterans and a key VA partnership to increase access to lung cancer screening. LUNGevity’s Scientific Advisory Board oversees the Foundation’s scientific strategy and ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of all people diagnosed with lung cancer. LUNGevity’s awardees are working to improve our ability to detect, diagnose, and treat lung cancer, as well as prevent its recurrence. LUNGevity is the only lung cancer non-profit with a long-term, strategic focus on the early detection of lung cancer. “We are thrilled to have Dr. Moghanaki join LUNGevity’s Scientific Advisory Board,” said Andrea Ferris, president of LUNGevity Foundation. “He brings expertise in radiation oncology as well as a deep knowledge of the VA healthcare system. We are excited to have his unique perspective and expertise to help guide our research program.” Read the full press release here.Dr. Drew Moghanaki joins LUNGevity Foundation Scientific Advisory Board
-
LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Alice T. Shaw, MD, PhD, has joined LUNGevity’s Scientific Advisory Board, a group of 20 world-renowned scientists and researchers that guides LUNGevity’s research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific strategy and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives of lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and Career Development Awards. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw performs clinical and translational research. Her clinical research focuses on subsets of NSCLC that have unique driver mutations, such as EGFR, ALK, and ROS1. Her translational research focuses on understanding and making clear the mechanisms of resistance to targeted therapies; she is currently developing novel combination treatment strategies. Her research has helped to develop numerous FDA-approved targeted therapies for patients with oncogene-driven NSCLC, such as crizotinib (Xalkori®) for patients with ALK or ROS1 rearrangements. “We could not be happier that Dr. Shaw has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “She is a brilliant thinker, an innovator, and a compassionate advocate for her patients. In particular, her groundbreaking work that led to the development of Xalkori® has extended and improved the lives of many NSCLC patients. Her expertise and counsel will advance LUNGevity’s goal to increase and improve survivorship for those affected by lung cancer.” Read the full press release here.
-
Edward Garon, MD, of UCLA joins the LUNGevity Foundation Scientific Advisory Board Dr. Garon brings expertise in clinical trials and other key areas to LUNGevity’s research program FOR IMMEDIATE RELEASE Media Contact: Austin Courtney acourtney@susandavis.com (202) 414-0791 WASHINGTON, DC (January 13, 2017) – LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Edward Garon, MD, has joined LUNGevity’s Scientific Advisory Board, a group of 19 world-renowned scientists and researchers who guide LUNGevity’s scientific strategy and research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific approach and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with programmatic focuses on early detection and Career Development Awards. LUNGevity-funded researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor of Medicine in the Division of Hematology-Oncology at David Geffen School of Medicine at UCLA. He has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials. Among these are trials that have led to the approval of drugs for the treatment of non-small cell lung cancer, including ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®). “We are honored that Dr. Garon has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “His expertise and advice will be invaluable to furthering LUNGevity’s goal to improve outcomes for lung cancer patients.” Click here to read the complete press release on LUNGevity.org.
